Real‑world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia
Clin Rheumatol. 2021. Epub ahead of print doi: 10.1007/s10067-021-05853-x
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Clin Rheumatol. 2021. Epub ahead of print doi: 10.1007/s10067-021-05853-x
Arthritis Res Ther. 2021;23(1):197
Rheumatology (Oxford). 2021;60(7):3209–21
RMD Open. 2021;7(2):e001609.
Rheumatol Ther. 2021;8(2):903–919
Ann Rheum Dis. 2021 May 28. DOI: 10.1136/annrheumdis-2021-220418
Clin Rheumatol. 2021 Jun 16. DOI: 10.1007/s10067-021-05815-3
N Engl J Med 2021; 385:130–41. doi: 10.1056/NEJMoa2102388
Bimekizumab was noninferior and superior to adalimumab with respect to PASI 90 response and IGA score at Week 16. Bimekizumab is a promising IL-17A/F inhibitor that has shown clinical improvement in PsO patients compared to placebo and other IL inhibitors. Warren et al. compared the safety and efficacy of bimekizumab with adalimumab in a 56-week double-blind trial.
Clin Exp Rheumatol. 2021;39(3):668-675.
Rheumatology (Oxford). 2021;60(5):2256-2266.